go back

Idecabtagene Vicleucel (Abecma), up to 460 Million Cells

Massachusetts rates for HCPCS C9081

Idecabtagene vicleucel, up to 460 million autologous anti-BCMA CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $436,516 · 10th–90th $436,516$436,5160%50%100%$436,516Professionalmedian $630,957 · 10th–90th $630,957$630,9570%50%100%$630,957$500.0K

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Small sample; interpret with caution. Need provider-level prices? Contact us.

Insurance Carrier
AllWays Health Partners
Setting
Facility
Modifier
Global
Typical Low
$436,515.83
Median
$436,515.83
Typical High
$436,515.83
AllWays Health Partners
Setting
Professional
Modifier
Global
Typical Low
$630,957.34
Median
$630,957.34
Typical High
$630,957.34
Mass General Brigham
Setting
Facility
Modifier
Global
Typical Low
$436,515.83
Median
$436,515.83
Typical High
$436,515.83
Mass General Brigham
Setting
Professional
Modifier
Global
Typical Low
$630,957.34
Median
$630,957.34
Typical High
$630,957.34